FDA Center for Biologics Evaluation and Research</a> to monitor and evaluate the safety and effectiveness of various vaccines, blood products, and other biologics. For this important public health collaboration, IQVIA worked with the Observational Health Data Science and Informatics initiative and its world-class team of healthcare experts and unique data assets from Columbia University, Stanford University, Georgia Institute of Technology, University of California, Los Angeles and the Regenstrief Institute at the Indiana University School of Medicine to enhance the function and outputs of the initiative.</p> <p><strong>Fighting the Opioid Epidemic:</strong> IQVIA partnered with the <a rel="noopener noreferrer" href=https://www.iqvia.com/ko-kr/about-us/"https://www.ama-assn.org/sites/default/files/media-browser/public/physicians/patient-care/opioid-task-force-progress-report.pdf" data-gc-link="https://www.ama-assn.org/sites/default/files/media-browser/public/physicians/patient-care/opioid-task-force-progress-report.pdf" target="_blank">American Medical Association’s Task Force to Reduce Opioid Abuse</a> to help reverse the nation’s opioid epidemic and provided valuable insight into the ongoing efforts to combat this public health crisis. Our data and analyses helped illustrate the effects of legislation regarding opioids.</p> <p><strong>Bridging Oncology Gaps: </strong><span>IQVIA has established the Cancer Data Network – a network that reveals insights that can help our oncology community improve cancer care and patient outcomes, accelerate clinical research and enable innovative contracting. IQVIA is a founding member of <a rel="noopener noreferrer" href=https://www.iqvia.com/ko-kr/about-us/"https://www.data-can.org.uk/" target="_blank">DATA-CAN</a>, the UK’s National Health Data Research Hub, and committed to developing the Cancer Data Network as part of the initiative.</span></p> <p><strong>Addressing Antibiotic Resistance:</strong> IQVIA collaborated with <a rel="noopener noreferrer" href=https://www.iqvia.com/ko-kr/about-us/"https://www.businesswire.com/news/home/20150602006417/en/IMS-Health-Data-Analytics-Drive-White-House" data-gc-link="https://www.businesswire.com/news/home/20150602006417/en/IMS-Health-Data-Analytics-Drive-White-House" target="_blank">the U.S. Centers for Disease Control and Prevention</a> and supported White House efforts to combat the overuse and misuse of antibiotics. Information and analysis identified significant regional and local variability in antibiotic use across the United States. The findings shed light on the driving factors behind the rising number of drug-resistant bacteria strains to better inform ongoing prevention efforts.</p> <p><strong>Assessing Disease Burden, Enabling Innovation:</strong> Tuberculosis is a major global public health challenge and India accounts for more than a quarter of these cases on an annual basis. As part of an effort funded by the Bill and Melinda Gates Foundation,<a rel="noopener noreferrer" href=https://www.iqvia.com/ko-kr/about-us/"http://www.thelancet.com/journals/laninf/article/PIIS1473-3099(16)30259-6/abstract" data-gc-link="http://www.thelancet.com/journals/laninf/article/PIIS1473-3099(16)30259-6/abstract" target="_blank"> IQVIA provided crucial information</a> about tuberculosis managed by the private sector to enable understanding of the true disease burden in the country, and around the world. The work revealed significantly higher rates of tuberculosis than had been previously recognized, as well as prospective causes, which can inform preventative protocols going forward.</p> <p><strong>Malaria Access in Action:</strong> Most malaria-endemic countries lack the ability to monitor the relationship between disease burden and the national supply and quality of critically needed medicines. To address this challenge, we collaborated with the <a rel="noopener noreferrer" href=https://www.iqvia.com/ko-kr/about-us/"https://www.mmv.org/access/products-projects/measuring-pharmaceutical-markets-africa" data-gc-link="https://www.mmv.org/access/products-projects/measuring-pharmaceutical-markets-africa" target="_blank">Medicines for Malaria</a> Venture to consolidate data flow and enable the Uganda National Drug Authority to complete the development of a system for monitoring pharmaceutical use at a national level.</p> <p><strong>Enabling Alzheimer’s Insights:</strong> <a rel="noopener noreferrer" href=https://www.iqvia.com/ko-kr/about-us/"http://ep-ad.org/" data-gc-link="http://ep-ad.org/" target="_blank">European Prevention of Alzheimer's Dementia (EPAD)</a> is a public-private consortium designed to better understand the early stages of Alzheimer’s disease and prevent dementia before symptoms occur. EPAD selected IQVIA to oversee a longitudinal study of 6,000 non-identified patients that enables researchers to track development of Alzheimer’s disease symptoms.</p>" /> FDA Center for Biologics Evaluation and Research</a> to monitor and evaluate the safety and effectiveness of various vaccines, blood products, and other biologics. For this important public health collaboration, IQVIA worked with the Observational Health Data Science and Informatics initiative and its world-class team of healthcare experts and unique data assets from Columbia University, Stanford University, Georgia Institute of Technology, University of California, Los Angeles and the Regenstrief Institute at the Indiana University School of Medicine to enhance the function and outputs of the initiative.</p> <p><strong>Fighting the Opioid Epidemic:</strong> IQVIA partnered with the <a rel="noopener noreferrer" href=https://www.iqvia.com/ko-kr/about-us/"https://www.ama-assn.org/sites/default/files/media-browser/public/physicians/patient-care/opioid-task-force-progress-report.pdf" data-gc-link="https://www.ama-assn.org/sites/default/files/media-browser/public/physicians/patient-care/opioid-task-force-progress-report.pdf" target="_blank">American Medical Association’s Task Force to Reduce Opioid Abuse</a> to help reverse the nation’s opioid epidemic and provided valuable insight into the ongoing efforts to combat this public health crisis. Our data and analyses helped illustrate the effects of legislation regarding opioids.</p> <p><strong>Bridging Oncology Gaps: </strong><span>IQVIA has established the Cancer Data Network – a network that reveals insights that can help our oncology community improve cancer care and patient outcomes, accelerate clinical research and enable innovative contracting. IQVIA is a founding member of <a rel="noopener noreferrer" href=https://www.iqvia.com/ko-kr/about-us/"https://www.data-can.org.uk/" target="_blank">DATA-CAN</a>, the UK’s National Health Data Research Hub, and committed to developing the Cancer Data Network as part of the initiative.</span></p> <p><strong>Addressing Antibiotic Resistance:</strong> IQVIA collaborated with <a rel="noopener noreferrer" href=https://www.iqvia.com/ko-kr/about-us/"https://www.businesswire.com/news/home/20150602006417/en/IMS-Health-Data-Analytics-Drive-White-House" data-gc-link="https://www.businesswire.com/news/home/20150602006417/en/IMS-Health-Data-Analytics-Drive-White-House" target="_blank">the U.S. Centers for Disease Control and Prevention</a> and supported White House efforts to combat the overuse and misuse of antibiotics. Information and analysis identified significant regional and local variability in antibiotic use across the United States. The findings shed light on the driving factors behind the rising number of drug-resistant bacteria strains to better inform ongoing prevention efforts.</p> <p><strong>Assessing Disease Burden, Enabling Innovation:</strong> Tuberculosis is a major global public health challenge and India accounts for more than a quarter of these cases on an annual basis. As part of an effort funded by the Bill and Melinda Gates Foundation,<a rel="noopener noreferrer" href=https://www.iqvia.com/ko-kr/about-us/"http://www.thelancet.com/journals/laninf/article/PIIS1473-3099(16)30259-6/abstract" data-gc-link="http://www.thelancet.com/journals/laninf/article/PIIS1473-3099(16)30259-6/abstract" target="_blank"> IQVIA provided crucial information</a> about tuberculosis managed by the private sector to enable understanding of the true disease burden in the country, and around the world. The work revealed significantly higher rates of tuberculosis than had been previously recognized, as well as prospective causes, which can inform preventative protocols going forward.</p> <p><strong>Malaria Access in Action:</strong> Most malaria-endemic countries lack the ability to monitor the relationship between disease burden and the national supply and quality of critically needed medicines. To address this challenge, we collaborated with the <a rel="noopener noreferrer" href=https://www.iqvia.com/ko-kr/about-us/"https://www.mmv.org/access/products-projects/measuring-pharmaceutical-markets-africa" data-gc-link="https://www.mmv.org/access/products-projects/measuring-pharmaceutical-markets-africa" target="_blank">Medicines for Malaria</a> Venture to consolidate data flow and enable the Uganda National Drug Authority to complete the development of a system for monitoring pharmaceutical use at a national level.</p> <p><strong>Enabling Alzheimer’s Insights:</strong> <a rel="noopener noreferrer" href=https://www.iqvia.com/ko-kr/about-us/"http://ep-ad.org/" data-gc-link="http://ep-ad.org/" target="_blank">European Prevention of Alzheimer's Dementia (EPAD)</a> is a public-private consortium designed to better understand the early stages of Alzheimer’s disease and prevent dementia before symptoms occur. EPAD selected IQVIA to oversee a longitudinal study of 6,000 non-identified patients that enables researchers to track development of Alzheimer’s disease symptoms.</p>" />
Global Public Health is at a critical inflection point, where opportunities and possibilities are greater than ever before. We have made great progress over the last decade to advance human health, but these advances still do not consistently reach the people who need them most and complex issues must be addressed.
At IQVIA, our mission is to accelerate the huge potential that can be achieved from reducing health inequities so that everyone can live longer, healthier lives. We believe in the power of scaling up innovation and working in collaboration across sectors to build more resilient, inclusive and sustainable healthcare systems.
Through our local geographical footprint and deep expertise in healthcare systems of the communities in which we serve, the IQVIA Global Public Health team is committed to unlocking extensive capabilities in clinical research, data, analytics, and technology to address complex issues and drive sustainable change through collaboration across a diverse healthcare ecosystem.
We work to bring innovative solutions and connected intelligence to the people who need it most.
Through collaboration, IQVIA hope to overcome some of the biggest challenges facing global public health. To support this, IQVIA has partnered with The Global Fund and (RED) supporting initiatives to strengthen healthcare across low- and middle-income countries, including in Africa. Innovative initiatives, such as the Data Science Catalytic Fund, implemented by The Global Fund in collaboration with the Rwandan government, will support technological advances and innovation in local healthcare systems, paving the way for transformative advances in patient care. This initiative will help with the crucial, rapid detection and response to disease outbreaks. We are committed to doing our part by harnessing our resources and expertise to identify, understand, and address unmet public health needs. Watch this video to learn more.
We build local collaborations by bringing together governments, international organizations, business leaders, advocacy groups, and academia to drive better healthcare outcomes for patients and communities globally.
Using our global footprint and breadth of expertise across the healthcare continuum, we apply connected intelligence to provide creative, differentiated and bespoke solutions that meet local requirements.
Our experience navigating diverse, local landscapes enables us to understand, and meet the needs, of patients and communities better and faster. Through our local footprint and the breadth and depth of our services and capabilities, we are able to address some of global public health’s most pressing challenges.